Medroxalol (Synonyms: RMI81968) |
| Catalog No.GC65874 |
Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist, blocks α- and β-adrenergic receptors. Medroxalol shows antihypertensive and vasodilating effects.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 56290-94-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist, blocks α- and β-adrenergic receptors. Medroxalol shows antihypertensive and vasodilating effects[1].
Medroxalol (0.1-10 μM; 20 min) shows α- and β-adrenergic receptor antagonism in isolated rabbit aortic strip[1].
Cell Viability Assay[1]
| Cell Line: | Isolated rabbit aortic strip |
| Concentration: | 0.1-10 μM |
| Incubation Time: | 20 min |
| Result: | Showed pA2 values of 6.09 and 7.73 for α-adrenergic receptors and β-adrenergic receptors, respevtively. |
Medroxalol (oral gavage; 12.5-50 mg/kg; once daily; 12 d) treatment shows antihypertensive activity in spontaneously hypertensive rats[1].
| Animal Model: | Male spontaneously hypertensive rats (SHR)[1] |
| Dosage: | 12.5, 25, or 50 mg/kg |
| Administration: | Oral gavage; 12.5, 25, or 50 mg/kg; once daily; 12 days |
| Result: | Produced a dose-related fall in blood pressure. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *